Target intelligence / Profile preview

Snake venom

Molecular classification
Other, Enzyme, Toxin, Peptide, Proteinase
01

Overview

Snake venom is a complex mixture of proteins, peptides, and other molecules produced by the venom glands of snakes. It serves primarily for prey immobilization, predigestion, and defense, acting via diverse mechanisms such as neurotoxicity, cytotoxicity, and hemostatic disruption. Snake venoms have been extensively studied for their biomedical potential, yielding drugs for hypertension, thromboembolic disorders, acute coronary syndromes, and chronic pain, among others. Key therapeutic challenges include compositional variability, difficulty of standardization, and inherent toxicity. While the whole venom is not a target, many individual toxin components have been successfully developed into life-saving therapeutics[1][2][3][7].

Other names
Snake venomsOphidian venomVenomous snake secretion
02

Mechanism of action

Enzyme (ACE) inhibition (e.g., captopril) - Glycoprotein IIb/IIIa antagonism (e.g., tirofiban, eptifibatide) - Defibrinogenation (e.g., ancrod, batroxobin) - Direct thrombin inhibition - Modulation of immune response - Inhibition of platelet aggregation - Cytolysis and apoptosis induction in cancer cells[1][7]

03

Biological functions

CytotoxicityNeurotoxicityHemotoxicityEnzyme inhibition/activationImmune modulationAnticoagulationProcoagulationAnalgesia
04

Disease associations

CancerInflammationCardiovascular disease (coagulation/thromboembolic disorders)Neurological disorders (e.g., pain, epilepsy, myasthenia gravis)InfectionStrokeDiabetes
05

Safety considerations

High toxicity and risk of systemic envenomation (coagulopathy, hemorrhage, neurotoxicity)Immunogenicity and allergic reactions to venom-based drugsVariability in composition leading to challenges in standardization and dosingRegulatory and manufacturing challenges (especially for antivenoms)
06

Interacting drugs

Captopril (hypertension)

7 more in the full profile.

07

Biomarkers

None specific for “snake venom” as a whole; individual venom components may have biomarkers for efficacy or monitoring, often disease- or drug-specific[1][7]

Beyond the preview

Go deeper on Snake venom.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Snake venom.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call